Vasomune Therapeutics, Inc.

Vasomune is a private biopharmaceutical company developing the next generation of medications to harness the body’s ability to defend against illness.

[Vasomune Therapeutics, Inc. @vasomune]

https://t.co/gucE3esgh0

[Vasomune Therapeutics, Inc. @vasomune]

Health Canada approves a new trial for Pegevongitide (AV-001) — a made-in-Canada therapy co-developed by Vasomune & AnGes — to protect hemodialysis patients from brain injury by stabilizing the cerebrovasculature.

[OBIO @OBIOscience]

🧬Next up as part of our #GlobalBiotechWeek celebration is @vasomune who reached the milestone of receiving U.S. FDA Fast Track Designation for their novel investigational medicine AV-001. 👏🏽 We're proud of Vasomune, an #OBIO member, as they continue to advance to the next phase!

[Vasomune Therapeutics, Inc. @vasomune]

Vasomune Therapeutics, Inc. is proud to be in Florida presenting our work at the 2024 Military Health System Research Symposium! With their support we have come a long way from preclinical to Phase 2a with AV-001 for the prevention and treatment of ARDS.
https://t.co/QqGIEm9uEJ

[Vasomune Therapeutics, Inc. @vasomune]

Thank you @ARDSALliance and @PaulaBlonski for striving against ARDS, and for reminding us why continued research into prevention and treatment is so important.
https://t.co/Z0CTdRYxz3

[Vasomune Therapeutics, Inc. @vasomune]

MHSRS-24-11804 (Full title in article) at 2024 Military Health System Research Symposium. Read more in the link below.
https://t.co/dZKPKwGQxq

[OBIO @OBIOscience]

👏🏽Congratulations to @vasomune on this milestone! We are proud of #OBIO member, Vasomune, as they receive U.S. FDA Fast Track Designation for AV-001. Looking forward to seeing you advance to the next phase!

[MaRS @MaRSDD]

Ft. @brogoz (CEO of @oncoustics), Alison Smith (co-founder and chief scientist at Roga), @FelixBL92 (CEO of @altislabs), Adam Forman (co-founder of Synakis) and Brian Jahns (COO of @vasomune).

[MaRS @MaRSDD]

These five startups are working on solutions that could speed up diagnosis, develop promising new therapeutics and improve patient care. Check them out at #MaRSImpactHealth happening June 12 and 13.

https://t.co/DqzmMM4NVS

[Genesys Capital @GenesysCapital]

This week @AstraZeneca completed the acquisition of Genesys portfolio company @FusionPharmaInc for US$2.4B! What a journey it has and we're thrilled to see Ontario becoming a global hub of excellence for radiopharmaceuticals.

https://t.co/WSRu7onER5

[Vasomune Therapeutics, Inc. @vasomune]

On Monday, June 5th at 3pm PST, Dr Brian Jahns presents the Vasomune Therapeutics story. Join Brian in Theatre 3 for the story of how Vasomune achieved the Fast Track Designation for pneumonia ARDS, and what his vision for the future is.
https://t.co/RzrbC80oVF

[MaRS @MaRSDD]

Congratulations to biopharmaceutical company @vasomune for receiving Fast Track designation by the @US_FDA for investigational medicine AV-001, which aims to address (and prevent) acute respiratory distress syndrome (ARDS).

[Vasomune Therapeutics, Inc. @vasomune]

@MaRSDD @US_FDA Thank you for your support. As part of the MaRS DD Community, we're intensely proud of this Made-in-Canada Bench-to Bedside story!

[Vasomune Therapeutics, Inc. @vasomune]

Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001 https://t.co/ar0eJkSqM6

[マネーのほこたて @mhokotate1]

アンジェス---Vasomuneとの共同開発品「AV-001」が米国呼吸器学会でポスター発表 - 最新株式ニュース https://t.co/vACHnk9IB9

[Vasomune Therapeutics, Inc. @vasomune]

On May 21, 2024, Vasomune's Dr. Harold Kim will present Phase 1 safety, and pharmacokinetic and pharmacodynamic data for AV-001 as a late-breaking scientific poster at the American Thoracic Society Clinical and Scientific sessions.

https://t.co/0bNJO2LsTJ

[Vasomune Therapeutics, Inc. @vasomune]

The agenda may be found at: https://t.co/UFnjZUKaM7

[Vasomune Therapeutics, Inc. @vasomune]

Vasomune Therapeutics' Dr Harold Kim, has been selected by the American Thoracic Society to showcase our lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit. Dr. Harold Kim, will speak on May 18th, at 11:30 AM PT, at the Manchester Grand Hyatt, San Diego, CA.

[Vasomune Therapeutics, Inc. @vasomune]

We are pleased to announce that the Independent Data and Safety Monitoring Board recommended the continuation of the Phase 2a trial (NCT05123755) evaluating the efficacy, safety, and tolerability of AV-001 in patients suffering with Acute Respiratory... https://t.co/Ld47U8Gumw

[Vasomune Therapeutics, Inc. @vasomune]

Vasomune Therapeutics doses first patient in Phase 2a clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease.
https://t.co/AlEI2dpPB8